{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:22:12Z","timestamp":1791602532695,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002564","name":"Alternatives Research and Development Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005932","name":"Johns Hopkins University Center for Alternatives to Animal Testing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005932","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030780","name":"Wetenschappelijk Fonds Willy Gepts, Universitair Ziekenhuis Brussel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011878","name":"Vlaamse regering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["963845"],"award-info":[{"award-number":["963845"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.tox.2025.154210","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T12:06:28Z","timestamp":1748952388000},"page":"154210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["In vitro test battery for testing molecular initiating events in chemical-induced cholestasis"],"prefix":"10.1016","volume":"517","author":[{"given":"Amy","family":"Maerten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Drees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julen","family":"Sanz-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Devisscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Vinken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tox.2025.154210_bib1","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/hep.26160","article-title":"Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells","volume":"57","author":"Anth\u00e9rieu","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2025.154210_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tox.2014.03.007","article-title":"Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity","volume":"320","author":"Arias","year":"2014","journal-title":"Toxicology"},{"key":"10.1016\/j.tox.2025.154210_bib3","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1124\/dmd.114.058123","article-title":"Impact of inflammation on chlorpromazine-induced cytotoxicity and cholestatic features in HepaRG cells","volume":"42","author":"Bachour-El Azzi","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2025.154210_bib4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.yrtph.2015.04.004","article-title":"Increasing scientific confidence in adverse outcome pathways: application of tailored Bradford-Hill considerations for evaluating weight of evidence","volume":"72","author":"Becker","year":"2015","journal-title":"Regul. Toxicol. Pharm."},{"key":"10.1016\/j.tox.2025.154210_bib5","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.2105\/AJPH.2007.124537","article-title":"Adverse event detection in drug development: recommendations and obligations beyond phase 3","volume":"98","author":"Berlin","year":"2008","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.tox.2025.154210_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cld.2012.11.002","article-title":"Drug-induced cholestasis","volume":"17","author":"Bjornsson","year":"2013","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.tox.2025.154210_bib7","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1038\/s41598-020-60747-3","article-title":"High-throughput screening to predict chemical-assay interference","volume":"10","author":"Borrel","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tox.2025.154210_bib8","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1124\/dmd.116.071373","article-title":"Early alterations of bile canaliculi dynamics and the rho Kinase\/Myosin light chain kinase pathway are characteristics of Drug-Induced intrahepatic cholestasis","volume":"44","author":"Burbank","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2025.154210_bib9","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jcmgh.2022.07.007","article-title":"Prolonged administration of melatonin ameliorates liver phenotypes in cholestatic murine model","volume":"14","author":"Ceci","year":"2022","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tox.2025.154210_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1124\/dmd.111.040758","article-title":"In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans","volume":"40","author":"Dawson","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2025.154210_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1124\/jpet.110.166991","article-title":"Hepatic transport mechanisms of cholyl-L-lysyl-fluorescein","volume":"334","author":"De Waart","year":"2010","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.tox.2025.154210_bib12","doi-asserted-by":"crossref","first-page":"7678","DOI":"10.3748\/wjg.v23.i43.7678","article-title":"Resveratrol modifies biliary secretion of cholephilic compounds in sham-operated and cholestatic rats","volume":"23","author":"Dolezelova","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.tox.2025.154210_bib13","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.3390\/ijms22083821","article-title":"Active transport of hepatotoxic pyrrolizidine alkaloids in HepaRG cells","volume":"22","author":"Enge","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tox.2025.154210_bib14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1124\/dmd.113.054189","article-title":"The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity","volume":"42","author":"Garzel","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2025.154210_bib15","first-page":"152","article-title":"Testing in vitro tools for the prediction of cholestatic liver injury induced by non-pharmaceutical chemicals","author":"Gijbels","year":"2021","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.tox.2025.154210_bib16","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00204-019-02437-2","article-title":"Mechanisms and in vitro models of drug-induced cholestasis","volume":"93","author":"Gijbels","year":"2019","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tox.2025.154210_bib17","first-page":"1","article-title":"Mechanisms of drug-induced cholestasis","author":"Gijbels","year":"2019","journal-title":"Exp. Chol Res"},{"key":"10.1016\/j.tox.2025.154210_bib18","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s00204-024-03757-8","article-title":"Formation of functional, extended bile canaliculi, and increased bile acid production in sandwich-cultured human cryopreserved hepatocytes using commercially available culture medium","volume":"98","author":"Horiuchi","year":"2024","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tox.2025.154210_bib19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ijpharm.2015.09.042","article-title":"Enhancement effect of resveratrol on the intestinal absorption of bestatin by regulating PEPT1, MDR1 and MRP2 in vivo and in vitro","volume":"495","author":"Jia","year":"2015","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.tox.2025.154210_bib20","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1021\/jm300212s","article-title":"Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug\u2013drug interactions","volume":"55","author":"Karlgren","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tox.2025.154210_bib21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00204-024-03895-z","article-title":"Drug-induced cholestasis (DIC) predictions based on in vitro inhibition of major bile acid clearance mechanisms","volume":"99","author":"Kastrinou-Lampou","year":"2024","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tox.2025.154210_bib22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2131\/jts.42.427","article-title":"Mechanism-based risk assessment strategy for drug-induced cholestasis using the transcriptional benchmark dose derived by toxicogenomics","volume":"42","author":"Kawamoto","year":"2017","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.tox.2025.154210_bib23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/bdd.2333","article-title":"Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells","volume":"43","author":"Le V\u00e9e","year":"2022","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.tox.2025.154210_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2024.116989","article-title":"Triclosan exposure causes abnormal bile acid metabolism through IL-1\u03b2-NF-\u03baB-Fxr signaling pathway","volume":"284","author":"Liu","year":"2024","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"10.1016\/j.tox.2025.154210_bib25","first-page":"76","article-title":"Melatonin improves cholestatic liver disease via the gut-liver axis","author":"Liu","year":"2024","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.tox.2025.154210_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/bdd.527","article-title":"Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance\u2013associated protein 2","volume":"28","author":"Mano","year":"2007","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.tox.2025.154210_bib27","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/cpt.2584","article-title":"Effect of cyclosporin a and impact of dose staggering on OATP1B1\/1B3 endogenous substrates and drug probes for assessing clinical drug interactions","volume":"111","author":"Mochizuki","year":"2022","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.tox.2025.154210_bib28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/toxsci\/kfq269","article-title":"Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development","volume":"118","author":"Morgan","year":"2010","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2025.154210_bib29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/toxsci\/kft176","article-title":"A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development","volume":"136","author":"Morgan","year":"2013","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2025.154210_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.tiv.2015.04.014","article-title":"Drug biokinetic and toxicity assessments in rat and human primary hepatocytes and HepaRG cells within the EU-funded Predict-IV project","volume":"30","author":"Mueller","year":"2015","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.tox.2025.154210_bib31","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","article-title":"Cyclosporin a inhibits hepatitis b and hepatitis d virus entry by cyclophilin-independent interference with the NTCP receptor","volume":"60","author":"Nkongolo","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tox.2025.154210_bib32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1124\/dmd.32.3.291","article-title":"Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity","volume":"32","author":"Nozawa","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2025.154210_bib33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/cld.894","article-title":"The pathophysiology of cholestasis and its relevance to clinical practice","volume":"15","author":"Onofrio","year":"2020","journal-title":"Clin. Liver Dis. (Hoboken)"},{"key":"10.1016\/j.tox.2025.154210_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2019.104595","article-title":"Differential toxic effects of bile acid mixtures in isolated mitochondria and physiologically relevant HepaRG cells","volume":"61","author":"Penman","year":"2019","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.tox.2025.154210_bib35","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative CT method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.tox.2025.154210_bib36","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/1440-1681.13546","article-title":"Resveratrol suppresses cholestasis-induced liver injury and fibrosis in rats associated with the inhibition of TGF\u03b21\u2013Smad3\u2013miR21 axis and profibrogenic and hepatic injury biomarkers","volume":"48","author":"ShamsEldeen","year":"2021","journal-title":"Clin. Exp. Pharm. Physiol."},{"key":"10.1016\/j.tox.2025.154210_bib37","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/toxsci\/kfu122","article-title":"Different dose-dependent mechanisms are involved in early cyclosporine A-induced cholestatic effects in HepaRG cells","volume":"141","author":"Sharanek","year":"2014","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2025.154210_bib38","doi-asserted-by":"crossref","first-page":"24709","DOI":"10.1038\/srep24709","article-title":"Rho-kinase\/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs","volume":"6","author":"Sharanek","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tox.2025.154210_bib39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/toxsci\/kfv155","article-title":"Cellular accumulation and toxic effects of bile acids in cyclosporine A-treated HepaRG hepatocytes","volume":"147","author":"Sharanek","year":"2015","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2025.154210_bib40","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1021\/acs.molpharmaceut.7b00563","article-title":"Interaction of food additives with intestinal efflux transporters","volume":"14","author":"Sj\u00f6stedt","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.tox.2025.154210_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.960","article-title":"Quantitative understanding of HepaRG cells during drug-induced intrahepatic cholestasis through changes in bile canaliculi dynamics","volume":"10","author":"Sonoi","year":"2022","journal-title":"Pharm. Res Perspect."},{"key":"10.1016\/j.tox.2025.154210_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059432","article-title":"Comparison of human hepatoma HepaRG cells with human and rat hepatocytes in uptake transport assays in order to predict a risk of drug induced hepatotoxicity","volume":"8","author":"Szabo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tox.2025.154210_bib43","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.3390\/ijms22095038","article-title":"In vitro liver toxicity testing of chemicals: a pragmatic approach","volume":"22","author":"Tabernilla","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tox.2025.154210_bib44","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s11010-023-04682-7","article-title":"Melatonin attenuates cholestatic liver injury via inhibition of the inflammatory response","volume":"478","author":"Tan","year":"2023","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.tox.2025.154210_bib45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/tx4004165","article-title":"Classification of hepatotoxicants using HepG2 cells: a proof of principle study","volume":"27","author":"Van den Hof","year":"2014","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2025.154210_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2023.104465","article-title":"Optimization of an adverse outcome pathway network on chemical-induced cholestasis using an artificial intelligence-assisted data collection and confidence level quantification approach","volume":"145","author":"van Ertvelde","year":"2023","journal-title":"J. Biomed. Inf."},{"key":"10.1016\/j.tox.2025.154210_bib47","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1021\/acs.chemrestox.9b00148","article-title":"Industrial, biocide, and cosmetic chemical inducers of cholestasis","volume":"32","author":"Vilas-Boas","year":"2019","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2025.154210_bib48","first-page":"136","article-title":"Cholestatic liver injury induced by food additives, dietary supplements and parenteral nutrition","author":"Vilas-Boas","year":"2020","journal-title":"Environ. Int."},{"key":"10.1016\/j.tox.2025.154210_bib49","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2009.05.012","article-title":"New molecular insights into the mechanisms of cholestasis","volume":"51","author":"Wagner","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tox.2025.154210_bib50","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/aps.2014.119","article-title":"Resveratrol effectively attenuates \u03b1-naphthyl-isothiocyanate-induced acute cholestasis and liver injury through choleretic and anti-inflammatory mechanisms","volume":"35","author":"Wang","year":"2014","journal-title":"Acta Pharm. Sin."}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X25001696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X25001696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:09:13Z","timestamp":1760591353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X25001696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":50,"alternative-id":["S0300483X25001696"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2025.154210","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro test battery for testing molecular initiating events in chemical-induced cholestasis","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2025.154210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"154210"}}